

For use only of a Registered Medical Practitioner, Hospital, or Laboratory only.

Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

MOSQIVAC™

1. Generic Name

Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

2. Qualitative and quantitative composition

After reconstitution, 1 dose (0.5 mL) contains 25 micrograms of RTS,S^{1,2} adjuvanted with AS01E³.

¹ Portion of *P. falciparum* circumsporozoite protein fused with hepatitis B surface antigen (RTS), and combined with hepatitis B surface antigen (S)

² in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (*Saccharomyces cerevisiae*) by recombinant DNA technology

³ AS01E adjuvant is composed of *Quilaja saponaria* Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) (25 micrograms)

Excipients:

Powder:
Sucrose, polysorbate 80, disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate.

Suspension:

Dioleoyl phosphatidylcholine (DOPC), cholesterol, sodium chloride, disodium phosphate anhydrous, potassium dihydrogen phosphate, water for injections.

The powder is white.

The suspension is an opalescent, colourless to pale brownish liquid.

3. Dosage form and strength

MOSQIVAC™ is a suspension for intramuscular injection. Antigen component vial is supplied in lyophilized (powder) form & adjuvant component vial is supplied in suspension form. The antigen component vial is to be reconstituted with the accompanying vial of adjuvant suspension component. After reconstitution, MOSQIVAC™ vial contains 2 doses of 0.5 mL vaccine.

4. Clinical particulars

4.1 Therapeutic indication

MOSQIVAC™ is indicated for active immunisation of children aged 5 to 17 months against malaria caused by *Plasmodium falciparum* and against hepatitis B (see sections *Posology and method of administration*, *Special warnings and precautions for use* and *Pharmacodynamic properties*).

The use of MOSQIVAC™ should be based on official recommendations considering *Plasmodium falciparum* malaria epidemiology in different geographical areas.

4.2 Posology and method of administration

Posology

Vaccination in children from 5 to 17 months of age (at first dose):

- Three doses, each of 0.5 mL, should be given at monthly intervals.
- A fourth dose is recommended 18 months after the third dose.

WHO recommendation:

WHO recommends that the first dose of vaccine be administered from 5 months of age. There should be a minimum interval of 4 weeks between doses. The vaccine should be administered in a 3-dose primary schedule, with a fourth dose provided approximately 12–18 months after the third dose to prolong the duration of protection. However, there can be flexibility in the schedule to optimise delivery, for example, to align the fourth dose with other vaccines given in the second year of life. Children who begin their vaccination series should complete the 4-dose schedule.

Other paediatric population:

The safety and efficacy of MOSQIVAC™ in children younger than 6 weeks and older than 17 months of age (at first dose) have not been established.

Method of administration

MOSQIVAC™ is for intramuscular injection only.

The deltoid muscle is the preferred site for injection in children aged 5 months and older (see sections *Special warnings and precautions for use* and *Drugs interactions*).

For instructions on reconstitution of the medicinal product before administration, see section *Special precautions for disposal and other handling*.

4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section *Qualitative and quantitative composition*.

Hypersensitivity to any previous dose of MOSQIVAC™ or hepatitis B vaccines.

4.4 Special warnings and precautions for use

Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable effects) and a clinical examination.

As with other vaccines, vaccination with Malaria Vaccine (RTS,S/AS01E) *Plasmodium falciparum* and hepatitis B vaccine (recombinant, adjuvanted) should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

A history of febrile convulsions or a family history of convulsions does not constitute a

contraindication for the use of RTS,S/AS01E. Vaccinees, especially those with a history of febrile convulsions, should be closely followed up as vaccine-related fever may occur after vaccination (see section *Undesirable effects*). In case of fever, antipyretic measures should be initiated according to local guidelines.

Fever may follow each dose of RTS,S/AS01E (see section *Undesirable effects*). Clinical data generated with other paediatric vaccines suggest that the prophylactic use of paracetamol might reduce the immune response to vaccine antigens. The clinical relevance of this observation remains unknown. In absence of clinical data with RTS,S/AS01E, the routine use of prophylactic antipyretic medicinal products before vaccination is therefore not recommended.

Protection against Plasmodium falciparum malaria

MOSQIVAC™ does not provide complete protection against malaria caused by *Plasmodium falciparum* (see section *Pharmacodynamic properties*).

Protection against *Plasmodium falciparum* malaria wanes over time and vaccination may delay the acquisition of natural immunity (see section *Pharmacodynamic properties*). If symptoms compatible with malaria develop, appropriate diagnosis and treatment should be sought.

Data regarding the efficacy of RTS,S/AS01E are limited to children from sub-Saharan Africa.

MOSQIVAC™ will not protect against malaria caused by pathogens other than *Plasmodium falciparum*.

The use of other malaria control measures recommended locally should not be interrupted.

Protection against hepatitis B

MOSQIVAC™ should not be used for the prevention of hepatitis B in settings where prevention against malaria caused by *Plasmodium falciparum* is not sought. An immune response against hepatitis B may not be elicited in all vaccinees (see section *Pharmacodynamic properties*).

MOSQIVAC™ will not protect against hepatitis caused by other pathogens other than hepatitis B virus.

Meningitis

In clinical studies, meningitis (any aetiology) has been reported more frequently in the group vaccinated with three doses of RTS,S/AS01E up to 20 months post dose 1 (27 cases out of 11,439 vaccinees) compared with the control group (4 cases out of 6,096 vaccinees). A causal relationship to the vaccine has not been established.

Systemic immunosuppressive medications and immunodeficiency

There are no data in children receiving immunosuppressive treatment or children with immunodeficiencies other than HIV infection. In these children, it cannot be ruled out that efficacy is impaired. Limited data are available with HIV-infected children (see sections *Undesirable effects* and *Pharmacodynamic properties*).

Precautions for use

Do not administer the vaccine intravascularly, intradermally or subcutaneously.

Patients at risk of bleeding

As with other vaccines administered intramuscularly, RTS,S/AS01E should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.

Preterm infants

The potential risk of apnoea and the need for respiratory monitoring for 48 to 72 h should be considered when administering the first three doses to very preterm infants (born ≤ 28 weeks of gestation) who remain hospitalised at the time of vaccination and particularly for those with a previous history of respiratory immaturity.

Sodium and Potassium content

This vaccine contains potassium, less than 1 mmol (39 mg) per dose, that is to say essentially 'potassium-free'.

This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

4.5 Drugs interactions

Use with other vaccines

If RTS,S/AS01E is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.

RTS,S/AS01E can be given concomitantly with any of the following monovalent or combination vaccines including diphtheria (D), tetanus (T), whole cell pertussis (Pw), acellular pertussis (Pa), hepatitis B (HepB), *Haemophilus influenza* type b (Hib), oral polio (OPV), measles, rubella, yellow fever, rotavirus and pneumococcal conjugate vaccines (PCV). The co-administration of RTS,S/AS01E with PCV increases the risk of fever within 7 days post-vaccination (see section *Undesirable effects*).

Concomitant administration of rotavirus and pneumococcal conjugate vaccines with RTS,S/AS01E may reduce the antibody response to the circumsporozoite (CS) antigen of RTS,S/AS01E. The impact of this observation on the level of protection induced by RTS,S/AS01E is currently unknown.

Use with systemic immunosuppressive medications

In the absence of data, it cannot be ruled out that efficacy is impaired in children receiving immunosuppressive treatment.

Prophylactic administration of antipyretics

See section *Special warnings and precautions for use*.

4.6 Use in special populations (such as pregnant women, lactating women, paediatric patients, geriatric patients etc.)

Pregnancy and Lactation

There are no or limited amount of data from the use of RTS,S/AS01E in pregnant women. No animal studies were performed with RTS,S/AS01E with respect to reproductive toxicity.

RTS,S/AS01E is not intended for use in pregnant women or women of child bearing potential.

4.7 Effects on ability to drive and use machines

Not relevant.

4.8 Undesirable effects

Summary of the safety profile

In clinical studies, the most serious adverse reaction associated with RTS,S/AS01E was febrile seizures (within 7 days post-vaccination) (0.1%). The most commonly reported adverse reactions were fever (27%), irritability (14%) and injection site reactions such as pain (16%) and swelling (7%).

Tabulated list of adverse reactions

Adverse reactions after 3 doses

The safety profile presented in Table 1 is based on a pooled analysis of more than 11,000 children (aged 6 weeks to 17 months at first dose) who have been vaccinated in clinical studies with 3 doses of RTS,S/AS01E.

Adverse reactions reported are listed according to the following frequency:

Very common	≥ 1/10
Common	≥ 1/100 to < 1/10
Uncommon	≥ 1/1000 to < 1/100

Table 1: Adverse reactions reported after 3 doses of the vaccine

System Organ Class	Frequency	Adverse reactions
Metabolism and nutrition disorders	Common	decreased appetite
Psychiatric disorders	Very common	irritability
	Common	somnolence
Nervous system disorders	Uncommon	febrile convulsions (within 7 days post vaccination)
	Common	diarrhoea
Gastrointestinal disorders	Uncommon	vomiting
General disorders and administration site conditions	Very common	fever, injection site reactions (including swelling, erythema and pain)
	Uncommon	injection site induration

Other special populations

HIV-infected children

Data from clinical studies suggest that HIV-infected children are more likely to experience local and systemic reactogenicity (injection site pain and injection site erythema, fever, somnolence, irritability, decreased appetite) compared to children of unknown HIV infection status.

Description of selected adverse reactions

Fever

In a clinical study in infants aged 8-12 weeks, fever was reported more frequently in infants receiving PCV in co-administration with RTS,S/AS01E, DTPa/Hib and OPV simultaneously (26%), as compared to infants receiving only RTS,S/AS01E, DTPa/Hib and OPV (14%). The frequency of grade 3 fever on co-administration (defined as axillary temperature > 39.0°C) was ≤ 1%.

Adverse reactions after the 4th dose

Clinical data in more than 4200 children who received a fourth dose of RTS,S/AS01E shows that, following this dose, decreased appetite was reported more frequently (very common) compared to the rates observed after the first three doses. All other adverse reactions occurred at the same or lower frequency, as reported in Table 1.

4.9 Overdose

No case of overdose has been reported. In the event of overdose, monitoring of vital functions and possible symptomatic treatment is recommended.

5. PHARMACOLOGICAL PROPERTIES

5.1 Mechanism of action

RTS,S/AS01E is a pre-erythrocytic vaccine intended to limit the ability of *Plasmodium falciparum* to infect, mature and multiply in the liver by eliciting humoral and cellular immunity to the circumsporozoite (CS) protein, which is abundantly present at the surface of the sporozoite.

RTS,S/AS01E induces antibodies against hepatitis B surface antigen (anti-HBs antibodies).

5.2 Pharmacodynamic properties

Vaccine efficacy

In a Phase III randomized controlled double-blind study conducted at 11 centres in 7 sub-Saharan African countries with a wide range of transmission intensities, more than 15,000 children from two age groups (6-12 weeks and 5-17 months) were enrolled to evaluate efficacy and safety of RTS,S/AS01E when given according to a 0, 1, 2-month schedule. In addition, more than 4200 children (including children from both age groups) received a fourth dose, given 18 months after the third dose.

Children from the 6-12 weeks age group received RTS,S/AS01E concomitantly with DTPw-HepB+Hib and OPV vaccines.

The primary objective of the study was efficacy against first or only episode of clinical malaria over a follow-up period of 12 months after three doses in each age group.

The secondary objectives included efficacy against all episodes of clinical malaria, efficacy against severe malaria and efficacy against hospitalisation caused by malaria over different follow-up periods after three doses in each age group.

The efficacy of RTS,S/AS01E was evaluated in the context of high insecticide treated bed nets coverage (86% in the 6-12 weeks age group and 78% in the 5-17 months age group).

Infants aged 6-12 weeks (at first dose)

In infants aged 6-12 weeks, the vaccine efficacy (VE) against first or only episode of clinical malaria over 12 months of follow-up (co-primary objective) was 31% (97.5% CI: 24; 38).

A summary of the secondary objectives pertaining to VE over different follow-up

periods, in infants who received three doses only or three doses plus a fourth dose, is given in Table 2.

Table 2: Vaccine efficacy in infants aged 6-12 weeks at first dose

	Vaccine efficacy against all episodes of clinical malaria (95% CI)	Vaccine efficacy against severe malaria (95% CI)	Vaccine efficacy against hospitalisation caused by malaria (95% CI)
Over 12 months follow-up from dose 3 (ATP* cohort, N = 6003)	33% (26; 39)	37% (5; 58)	32% (7; 50)
Over 18 months follow-up from dose 3 (ATP* cohort, N=6003)	27% (20; 32)	15% (-20; 39)	17% (-7; 36)
3 doses only (ATP* cohort, N=5997)			
Over 30 months follow-up from dose 3	20% (13; 27)	11% (-22; 35)	10% (-15; 30)
Over 36 months follow-up** from dose 3	18% (11; 25)	13% (-17; 35)	13% (-9; 31)
3 doses + 4 th dose (ATP* cohort, N=5997)			
Over 30 months follow-up from dose 3	28% (22; 34)	17% (-14; 40)	25% (3; 42)
Over 36 months follow-up** from dose 3	27% (21; 32)	21% (-7; 42)	27% (7; 43)

* According-to-protocol (ATP) cohort: all infants immunised according to schedule, N= total number in all 3 study groups.

** The follow-up period from dose 3 to study end was not the same for all subjects because the study ended on a fixed date. The median length for this follow-up period is 36 months.

Children aged 5-17 months (at first dose)

In infants aged 5-17 months, the VE against first or only episode of clinical malaria over 12 months of follow-up (co-primary objective) was 56% (97.5% CI: 51; 60).

A summary of the secondary objectives pertaining to VE over different follow-up periods, in children who received three doses only or three doses plus a fourth dose, is given in Table 3.

Table 3: Vaccine efficacy in children aged 5-17 months at first dose

	Vaccine efficacy against clinical malaria (95% CI)	Vaccine efficacy against severe malaria (95% CI)	Vaccine efficacy against hospitalisation caused by malaria (95% CI)
Over 12 months follow-up from dose 3 (ATP* cohort, N=6880)	51% (47; 55)	45% (22; 60)	48% (35; 59)
Over 18 months follow-up from dose 3 (ATP* cohort, N=6885)	46% (42; 49)	36% (15; 51)	42% (29; 52)
3 doses only (ATP* cohort, N=6918)			
Over 30 months follow-up from dose 3	34% (29; 39)	2% (-28; 25)	18% (1; 32)
Over 46 months follow-up** from dose 3	26% (21; 31)	-6% (-35; 17)	12% (-5; 26)
3 doses + 4 th dose (ATP* cohort, N=6918)			
Over 30 months follow-up from dose 3	46% (42; 50)	32% (10; 50)	40% (26; 52)
Over 46 months follow-up** from dose 3	39% (34; 43)	29% (6; 46)	37% (24; 49)

* According-to-protocol (ATP) cohort: all children immunised according to schedule, N= total number in all 3 study groups.

** The follow-up period from dose 3 to study end was not the same for all subjects because the study ended on a fixed date. The median length for this follow-up period is 46 months.

Long-term follow-up of efficacy

The Phase III efficacy study was extended for 3 additional calendar years in 3 out of the 11 centres. Vaccine efficacy from the first vaccine dose given in the efficacy study to the end of the follow-up (median duration of follow-up: 6.2 years in infants aged 6-12 weeks at first dose and 6.8 years in children aged 5-17 months at first dose) is presented in Table 4.

Table 4: Vaccine efficacy from first vaccine dose to the end of the follow-up

	Vaccine efficacy against clinical malaria (95% CI)	Vaccine efficacy against severe malaria (95% CI)
Infants aged 6-12 weeks at first dose (ITT cohort, N= 1905)		
3 doses only	13% (4; 21)	34% (9; 53)
3 doses + 4 th dose	16% (7; 24)	31% (5; 50)
In children aged 5-17 months at first dose (ITT cohort, N= 2512)		
3 doses only	19% (11; 27)	10% (-18; 32)
3 doses + 4 th dose	24% (16; 31)	37% (15; 53)

ITT: Intent-to-treat population
N= total number of subjects

Vaccine-induced immunogenicity

No correlate of protection has currently been established.

Immunogenicity against the circumsporozoite (CS) protein

In the Phase III efficacy study, the geometric mean concentration (GMC) of antibodies against the circumsporozoite (CS) protein, was measured after the third dose of RTS,S/AS01₁ (month 3) as well as before and after the fourth dose (months 20 and 21) in a subset within each age group.

Antibody responses for each age group are given in Table 5.

Table 5: Antibody responses to RTS,S/AS01₁ (anti-CS antibody)

	anti-CS antibody GMC		
	one month after the third dose (month 3) (95% CI)	before the fourth dose (month 20) (95% CI)	one month after the fourth dose (month 21) (95% CI)
Infants (aged 6-12 weeks at first dose)	N=1221	N=530	N=503
	211 EU/ml (198; 224)	6 EU/ml (5; 7)	170 EU/ml (154; 188)
Children (aged 5-17 months at first dose)	N=1034	N=442	N=426
	621 EU/ml (592; 652)	34 EU/ml (31; 39)	318 EU/ml (295; 343)

N= total number of children/infants immunised according to schedule (ATP cohort) with available results

Immunogenicity against hepatitis B

The immunogenicity of RTS,S/AS01₁ following three doses has been evaluated in infants aged 8-12 weeks (at first dose). One month post-vaccination in the ATP cohort, 100% of the infants were seroprotected for hepatitis B (N=141). These infants did not receive any other hepatitis B antigen-containing vaccine.

Immunogenicity in special sub-populations

HIV infected children

In the Phase III efficacy study, children were not screened for HIV infection at enrolment.

Based on clinical data on 125 children with a confirmed HIV infection, RTS,S/AS01_E elicited a lower anti-CS antibody response in HIV-infected children (GMC=193 EU/ml) as compared with children of unknown HIV infection status (GMC=492 EU/ml), one month after the third dose of RTS,S/AS01_E.

In another clinical study, children with HIV infection stages 1 or 2, in the context of high treatment (anti-retrovirals and co-trimoxazole) coverage, were vaccinated with 3 doses of RTS,S/AS01_E (N=99) or rabies vaccine (N=101). The anti-CS antibody GMC was 329 EU/mL one month after the third dose. Over 12 months of follow-up after the third dose of RTS,S/AS01_E, VE against all episodes of clinical malaria was 37% (95% CI: -27; 69).

Preterm infants

The immunogenicity of RTS,S/AS01_E in 362 preterm infants born after a gestation period of less than 37 weeks (median 36 weeks, with a range of 27 to 36 weeks), was evaluated one month after the third dose. The vaccine induced a similar anti-CS response in preterm infants (GMC=262 EU/mL) as compared to infants born after at least 37 weeks of gestation (GMC=247 EU/mL).

Low weight-for-age (malnourished) children

The immune response to CS protein was comparable for normal, low and very low weight-for-age children. The efficacy of RTS,S/AS01_E is not expected to vary substantially according to weight-for-age.

5.3 Pharmacokinetic properties

Not applicable.

6. Nonclinical properties

6.1 Animal Toxicology or Pharmacology

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and local tolerance.

7. Description

MOSQIVACTM powder and suspension for reconstitution for injection

Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

see section Qualitative and quantitative composition

8. Pharmaceutical particulars

8.1 Incompatibilities

This medicinal product must not be mixed with other medicinal products.

8.2 Shelf-life

The expiry date of MOSQIVACTM is indicated on the label and carton of the vaccine.

8.3 Packaging information

- Powder for 2 doses in a vial (type I glass) with a stopper (bromobutyl rubber), aluminium seal with a flip-off polypropylene cap;
- 1 mL suspension for 2 doses in a vial (type I glass) with a stopper (chlorobutyl rubber), aluminium seal with a flip-off polypropylene cap.

8.4 Storage and handling instructions

Store in a refrigerator (2°C – 8°C).

Do not freeze.

Store in the original package in order to protect from light.

Keep out of the sight and reach of children.

According to official recommendations, once the vaccine has been reconstituted, it should be maintained between 2°C to 8°C and protected from the sunlight; the remaining, unused vaccine doses must be discarded at the end of each immunisation session or after 6 hours from reconstitution, whichever comes first.

Special precautions for disposal and other handling:

The powder and suspension should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not administer the vaccine.

MOSQIVACTM must be reconstituted prior to administration.

- Withdraw the entire contents of the vial containing the suspension into the syringe.
- Add the entire contents of the syringe into the vial containing the powder.
- Shake gently until the powder is completely dissolved.

The reconstituted vaccine is an opalescent, colourless to pale brownish liquid.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not administer the vaccine.

After reconstitution, immediate use is recommended. If not used immediately, the multi-dose vial must be discarded at the end of each immunisation session or after 6 hours from reconstitution, whichever comes first.


Each dose of 0.5 mL should be withdrawn using a sterile needle and syringe; precautions should be taken to avoid contamination of the contents.

A new needle should be used to administer each individual dose of the vaccine.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

The Vaccine Vial Monitor:

The Vaccine Vial Monitor (VVM) is part of the label of the suspension vial used for all MOSQIVACTM batches supplied by Bharat Biotech International Ltd. The colour dot that appears on the label of the suspension vial is a VVM. This is a time-temperature sensitive dot that provides an indication of the cumulative heat to which the vial has been exposed. It warns the end user when exposure to heat is likely to have degraded the vaccine beyond an acceptable level.



The interpretation of the VVM is simple. Focus on the central square. Its colour will change progressively. As long as the colour of this square is lighter than the colour of the outer circle, then the vaccine can be used. As soon as the colour of the central square is the same colour as the outer circle or of a darker colour than the outer circle, then the vial should be discarded.

9. Patient Counselling Information

Prior to the administration of this vaccine, the healthcare professional should inform the individual and his parents/guardians of the following:

- Educate vaccine recipients and their parent(s)/guardian(s) regarding the possible common adverse reactions occurring within 7 days' post-vaccination with MOSQIVACTM (febrile seizures, irritability and injection site reactions, etc) and to note for any uncommon adverse reaction if they are encountered.
- Instruct vaccine recipients and their parent(s)/guardian(s) to report any adverse reactions if encountered to their healthcare provider.

10. Details of manufacturer

Adjuvant Manufactured by:
GlaxoSmithKline Biologicals s.a.s
Rue de Aulnois, 637, Saint-Amand-lex-Eaux,
59230 France

Adjuvant imported, Packed & Vaccine Manufactured by:
Bharat Biotech International Ltd.
At: Plot No. 3502, G.I.D.C. Estate, Post Box No. 136,
Ankleshwar 393002, Dist. Bharuch, Gujarat, India.

Tested, Released & Marketed by:

Bharat Biotech International Ltd.
Sy.No. 230, 231 & 235, Genome Valley, Turkapally,
Shamirpet Mandal, Medchal - Malkajigiri District - 500 078,
Telangana State, India.

11. Details of permission or licence number with date

Licence No.: G/28DA/LVP/65-A
Date: 24-Jun-2026

12. Date of revision

July 2026

For complaints and suggestions about the product and any adverse event,
Please email feedback@bharatbiotech.com
www.bharatbiotech.com

TM - Trademark of Bharat Biotech International Ltd.